

APASL STC 2025 Tokyo

Oral Free Papers

No.	Style	First Name	Last Name	Country/District	Title of Abstract
10006	Oral	Lin	Guan	China	Non-targeted Metabolomics Sequencing Combined with 101 Machine Learning Algorithms to Analyse Key Metabolites in Varying Degrees of Non-alcoholic Fatty Liver Disease
10007	Oral	Zhe	Cheng	China	Xietu Hemu Prescription Suppresses Adipocytogenesis and Alleviates Dysregulation of Lipid Metabolism in Vitro through LEP/AMPK/PPARG Axis
10008	Oral	Yutian	Cao	China	Sex and Menopausal Differences in the Association between Visceral Adipose Tissue and Metabolic Dysfunction-associated Steatotic Liver Disease: A Cross-sectional and Mendelian Randomization Study
10009	Oral	Jiaying	Wang	China	Mechanism of TRPML1 in MAFLD: AMPK-Mediated Regulation of Autophagy and Lipid Metabolism
10010	Oral	Ji	Sun	China	DHX9 Loads Hepatocyte-derived Exosomal miR-106b to Activate Hepatic Stellate Cells via Actin Cytoskeleton in MASLD
10012	Oral	Tiansu	Lv	China	Potential Targets in Metabolic-Associated Steatohepatitis Based on Bioinformatics Analysis and Machine Learning Strategies
10014	Oral	Weilong	Xu	China	Myricetin Ameliorates MASLD by Enhancing Mitochondrial Function and Promoting PINK1/Parkin-dependent Mitophagy
10025	Oral	Michiko	Ishii	Japan	Development and Characterization of a Murine Model of Anorexia Nervosa-Associated Microvesicular Steatosis
10036	Oral	Mengyi	Shen	China	Engineering Vesicle-Mediated Metabolic Regulation and Immune Targeting for the Treatment of Autoimmune Hepatitis
10057	Oral	Yuki	Matsushita	Japan	The Risk of Decompensation in Steatotic Liver Disease-related Hepatocellular Carcinoma after Curative Treatment
10058	Oral	Nguyen	Bui Tam Chi	Japan	Role of Recombinant Human Cytoglobin against Acetaminophen-induced Liver Injury
10065	Oral	Sunita	Giri	India	Deregulation of FTO Isoforms in the Progression of Nonalcoholic Fatty Liver Disease to Nonalcoholic Steatohepatitis and its Amelioration with Entacapone
10071	Oral	Fawaz	Haj	USA	Deficiency of Hepatic Protein Tyrosine Phosphatase 1B is Protective in a Mouse Model of MASH
10078	Oral	Seohui	Jang	Korea	Dynamic Changes in Steatotic Liver Disease Subtypes and Risk of Cardiovascular Disease: A Nationwide Cohort Study
10080	Oral	Jeongin	Lee	Korea	The Risk of Heart Failure in Patients with Atrial Fibrillation According to the Steatotic Liver Disease Subtype
10091	Oral	Tatia	Khachidze	Georgia	Gut Microbiota Dysbiosis and Its Role in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease
10095	Oral	Jirayu	Sriphaiboon	Thailand	Clinical Significance of Leptin Receptors and Promoting Roles of Leptin in Hepatocellular Carcinoma
10102	Oral	Yoshiko	Nakamura	Japan	Pathological Classification of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Based on Muscle Fatty Changes and Quantitative Changes Using MRI: A Cluster Analysis Study
10111	Oral	Jin-Hyun	Park	Korea	Handgrip Strength Estimation as a Predictor of Liver-Related Outcomes in Patients with Steatotic Liver Disease
10112	Oral	Seokjin	Kong	Korea	Differential Effects of Antihypertensive Drug Classes on Liver-related Outcomes in MASLD/MetALD Patients with Hypertension
10119	Oral	Michitaka	Matsuda	Japan	Wilms Tumor 1 Induces Hepatic Stellate Cell Invasion that Develops Bridging Fibrosis in Chronic Liver Injury
10122	Oral	Navia	Vinoy	Australia	A Novel PEX13 Knockout Liver Cell Line Generated Using CRISPR Prime Editing Provides New Insights into Steatotic Liver Disease
10130	Oral	Mohamed	Abdel-Samiee	Egypt	Micro-RNA Gene Polymorphisms and Development of Hepatocellular Carcinoma in Egyptian Patients with Chronic Viral Hepatitis
10148	Oral	Vikas	Sharma	India	AI-Integrated Biosensor Wearables for Monitoring Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Type 1 Diabetes
10149	Oral	Vikas	Sharma	India	The Role of Wearable Technology and Geo-Fencing in Physiological Monitoring and Pre-Transplant Optimization for Adolescents with NAFLD Undergoing Bariatric Surgery
10153	Oral	Noriyoshi	Ogino	Japan	Neutrophil Elastase Undergoes Endocytosis into Hepatocytes and Contributes to Liver Injury in Alcoholic Hepatitis
10159	Oral	Masahiro	Yanagi	Japan	Effects of Hydroxynonenal on Hepatic Macrophages in the Pathogenesis of MASLD
10160	Oral	Tomoo	Yamazaki	USA	Single Nuclei RNA Sequencing Shows the Engagement of PPAR $\delta$ Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR $\delta$ Agonist Seladelpar
10161	Oral	Mark D	Gorrell	Australia	A Novel Fibrosis NIT that Uses the Myofibroblast Marker Fibroblast Activation Protein (FAP) and FIB4 in Metabolic Associated Steatotic Liver Disease
10162	Oral	Hongping	Xia	China	Understanding the Microenvironment and Progression of Liver Fibrosis to Cancer for Developing Novel Precision Therapy
10163	Oral	Balasubramanian	Vairappan	India	Pharmacological Inhibition of Hepatic DGAT2 Reduces Triglyceride Synthesis and Attenuates MAFLD Progression in Mice
10174	Oral	Jordan	Low	Singapore	Gender-Specific Body Composition Phenotypes Predict Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis: A Cross-Sectional MRI-Based Clustering Analysis
10177	Oral	Taisei	Iwasa	Japan	Development of Overt Hepatic Encephalopathy Increases Mortality in Patients with Cirrhosis: A Multicenter Retrospective Cohort Study
10181	Oral	Sangwook	Cheon	Korea	Risk Factors for Cardiovascular Disease Among Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Cohort Study
10182	Oral	Jun	Arai	Japan	Natural Killer Activating Receptor Ligands are Promising Biomarkers to Predict the Pathogenesis of At-risk MASH
10197	Oral	Vikas	Kumar	India	Columbinadin-Loaded Solid Lipid Nanoparticles Ameliorate Non-Alcoholic Fatty Liver Disease via Modulation of HO-1/Nrf2 and PGE2/TLR4/NF- $\kappa$ B Signaling Pathways
10205	Oral	Kamal	Parvej	Bangladesh	Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Angiographic Severity of Coronary Artery Disease in Acute Coronary Syndrome
10206	Oral	Yichu	Kao	Taiwan	IL-1R1 Deficiency Attenuates Hepatic Ischemia-Reperfusion Injury by Coordinating Oxidative Stress Control, Hepatocyte Regeneration, and Immune Rebalancing
10207	Oral	Selvakumar	Vigneshwaran	Singapore	A Proof of Concept for Ultrasound Based Artificial Intelligence Quantification of Liver Steatosis and Fibrosis
10213	Oral	Jin Hyeok	Choi	Korea	Association of Combustible Cigarette and Noncombustible Tobacco Product Use With Mental Health Outcomes in Subtypes of Fatty Liver Disease: A Nationwide Cohort Study From Korea
10221	Oral	Mona	Munteanu	USA	Noninvasive Initiation and Monitoring of the Therapy with TNR-beta Agonist Resmetirom (RT) Using LIVERFAST (LFAST), FIB-4 and Vibration-controlled Transient Elastography (VCTE, Fibroscan) in Patients with MASH

\*Further details of Oral Free Papers Program will be announced soon.